All In Biotech

Drug Trial Radar · NCT07235202

A Study of MR001 Combined With Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) After First-line Therapy

An Open-label, Dose-escalation and Dose-expansion Phase Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of MR001 in Combination With Standard Chemotherapy Regimens in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Who Have Progressed After First-line Therapy

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

45

Planned (sponsor's estimate)

Start

Dec 24, 2025

Primary completion

Jun 22, 2028

Study completion Dec 22, 2028

Sponsor

Sponsor type
Industry
First posted
Nov 19, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase Ib/IIa study is evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of MR001 Combined with Chemotherapy in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) who have progressed after first-line therapy.

Conditions

  • Pancreatic Ductal Adenocarcinoma (PDAC)

Interventions

  • MR001Drug

    Intravenous infusion

  • Irinotecan Liposome Injection combined with 5-FU/LVDrug

    Per locally approved formulation

  • Nab-paclitaxelDrug

    Per locally approved formulation

  • Gemcitabine (GEM)Drug

    Per locally approved formulation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants who experience one or more dose-limiting toxicities (DLTs)Time frame: Approximately 12 months
  2. Maximum Tolerated Dose (MTD) of MR001Time frame: Approximately 12 months
  3. Incidence of Adverse Events (AEs) as Assessed by CTCAE v5.0Time frame: Approximately 30 months
  4. Objective Response Rate (ORR)Time frame: Approximately 24 months
  5. Best Overall Response (BOR)Time frame: Approximately 24 months
  6. Disease control rate (DCR)Time frame: Approximately 24 months

Locations

18 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Tsinghua Changgung Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Chongqing University Cancer Hospital

    Chongqing, Chongqing Municipality, China · Not yet recruiting

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China · Not yet recruiting

  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University

    Guangzhou, Guangdong, China · Recruiting

  • Shenzhen People's Hospital

    Shenzhen, Guangdong, China · Not yet recruiting

  • Cancer Hospital Chinese Academy of Medical Sciences,Shenzhen

    Shenzhen, Guangdong, China · Not yet recruiting

  • The Fourth Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China · Recruiting

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China · Recruiting

  • Henan Cancer Hospital

    Zhengzhou, Henan, China · Not yet recruiting

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China · Not yet recruiting

  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China · Not yet recruiting

  • Hunan Cancer Hospital

    Changsha, Hunan, China · Not yet recruiting

  • The First Hospital of Jilin University

    Changchun, Jilin, China · Not yet recruiting

  • The First Hospital of China Medical University

    Shenyang, Liaoning, China · Not yet recruiting

  • Shandong Cancer Hospital

    Jinan, Shandong, China · Not yet recruiting

  • West China Hospital of Sichuan University

    Chengdu, Sichuan, China · Not yet recruiting

  • The Second People's Hospital of Yibin

    Yibin, Sichuan, China · Not yet recruiting

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.